Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05676476 · ClinicalTrials.gov registry record · NA

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

A NA study of Preeclampsia and Gestational Hypertension, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
132
Enrollment target
2
Study locations

NCT05676476 is a NA study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 132 participants, below the 1,279-participant average among 39 other Preeclampsia trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05676476, a NA study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
132 participants
Enrollment target
2
Study locations

Study Summary

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

Interventions

  • DRUG Antihypertensive treatment

Study Locations (2)

Alabama

  • University of Alabama at Birmingham - Birmingham

Louisiana

  • Oschner - New Orleans

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2023-02-14
Est. Completion 2027-06
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT05676476

The ClinicalTrials.gov registry entry for NCT05676476 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,279-participant average among 39 other Preeclampsia trials with a reported enrollment target (90% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Antihypertensive treatment is the first listed.

NCT05676476 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05676476 about?

NCT05676476 is a clinical study titled "The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.". The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

What is the current status of trial NCT05676476?

This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-02-14. Estimated completion is 2027-06.

What conditions does trial NCT05676476 study?

This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy.

What interventions are being tested in trial NCT05676476?

The interventions under investigation include: Antihypertensive treatment (DRUG).

Who is sponsoring clinical trial NCT05676476?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05676476 being conducted?

This trial has 2 study locations across Alabama, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.